Somatostatin analogs inhibit somatostatin release

E. Ipp, J. Rivier, R. E. Dobbs, M. Brown, W. Vale, Roger H Unger

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


To determine if, like insulin, somatostatin inhibits its own secretion from the pancreas, nonimmunoreactive analogs of somatostatin were perfused in an isolated dog pancreaticoduodenal preparation using a nonrecirculating system. [D-Trp8-D-Cys14]somatostatin, at a concentration of 200 ng/ml, blocked the response of somatostatin-like immunoreactivity (SLI) to cholecystokinin and arginine. When perfusion of the analog was discontinued, SLI release increased. At a concentration of 0.1 ng/ml, des Asn5-[D-Trp8]somatostatin lowered SLI levels significantly without significantly reducing glucagon levels. At a concentration of 1 ng/ml, des Asn5-[D-Trp8]somatostatin significantly inhibited SLI as well as insulin and glucagon release. Perfusion of glucagon at a concentration of 10 ng/ml failed to overcome the blockade of SLI and insulin release caused by 50 ng/ml des Asn5-[D-Trp8]somatostatin. The results are compatible with a direct inhibitory effect of somatostatin analogs upon SLI release and raise the possibility of a self-inhibiting action of the native hormone.

Original languageEnglish (US)
Pages (from-to)1270-1273
Number of pages4
Issue number5
StatePublished - May 1979

ASJC Scopus subject areas

  • Endocrinology


Dive into the research topics of 'Somatostatin analogs inhibit somatostatin release'. Together they form a unique fingerprint.

Cite this